收费全文 | 331440篇 |
免费 | 29572篇 |
国内免费 | 11844篇 |
耳鼻咽喉 | 2183篇 |
儿科学 | 7237篇 |
妇产科学 | 3989篇 |
基础医学 | 56970篇 |
口腔科学 | 6517篇 |
临床医学 | 26635篇 |
内科学 | 50967篇 |
皮肤病学 | 4511篇 |
神经病学 | 22205篇 |
特种医学 | 6675篇 |
外国民族医学 | 78篇 |
外科学 | 25927篇 |
综合类 | 46371篇 |
现状与发展 | 38篇 |
一般理论 | 25篇 |
预防医学 | 18931篇 |
眼科学 | 6279篇 |
药学 | 39582篇 |
33篇 | |
中国医学 | 13904篇 |
肿瘤学 | 33799篇 |
2024年 | 745篇 |
2023年 | 4538篇 |
2022年 | 9524篇 |
2021年 | 12506篇 |
2020年 | 10731篇 |
2019年 | 12032篇 |
2018年 | 11581篇 |
2017年 | 11415篇 |
2016年 | 11408篇 |
2015年 | 12789篇 |
2014年 | 18539篇 |
2013年 | 20913篇 |
2012年 | 18468篇 |
2011年 | 21710篇 |
2010年 | 18616篇 |
2009年 | 17898篇 |
2008年 | 17402篇 |
2007年 | 17338篇 |
2006年 | 15833篇 |
2005年 | 14493篇 |
2004年 | 12571篇 |
2003年 | 11027篇 |
2002年 | 8432篇 |
2001年 | 7811篇 |
2000年 | 6408篇 |
1999年 | 5894篇 |
1998年 | 4546篇 |
1997年 | 4106篇 |
1996年 | 3896篇 |
1995年 | 3518篇 |
1994年 | 3092篇 |
1993年 | 2706篇 |
1992年 | 2314篇 |
1991年 | 2045篇 |
1990年 | 1698篇 |
1989年 | 1540篇 |
1988年 | 1398篇 |
1987年 | 1087篇 |
1986年 | 926篇 |
1985年 | 1339篇 |
1984年 | 1397篇 |
1983年 | 936篇 |
1982年 | 1094篇 |
1981年 | 897篇 |
1980年 | 753篇 |
1979年 | 638篇 |
1978年 | 510篇 |
1977年 | 406篇 |
1976年 | 423篇 |
1975年 | 280篇 |
Background
Bone mineral density (BMD) has been found to improve after parathyroidectomy (PTX) in patients with primary hyperparathyroidism. There are few data on the effect of PTX on BMD in normocalcemic and normohormonal primary hyperparathyroidism.Methods
A retrospective analysis of 92 primary hyperparathyroidism patients who underwent PTX between 2004 and 2012 with pre- and post-PTX dual-energy x-ray absorptiometry was performed. Within-person changes in BMD pre- and post-PTX were analyzed using log linear mixed models, stratified by biochemical status.Results
Bone mineral density increased post-PTX in the whole cohort at the lumbar spine (+2.5%), femoral neck (+2.1%), and total hip (+1.9%) and decreased at the one-third radius (–0.9%). On comparison of BMD changes by profile, BMD increased in those with the typical profile at the lumbar spine (3.2%), femoral neck (2.9%), and total hip (2.9%) but declined at the one-third radius (–1.5%). In contrast, BMD improved only at the femoral neck (4.3%) in the normohormonal group and did not change at any site in the normocalcemic group. The typical group had a greater increase in BMD over time at the femoral neck and total hip compared with normocalcemic patients.Conclusion
Our results indicate that the skeletal benefit of PTX was attenuated in normocalcemic and normohormonal patients, suggesting that skeletal changes after PTX may depend on biochemical profile. 相似文献Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献